LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Aktien・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Geschlossen

3.75 7.14

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.67

Max

3.76

Schlüsselkennzahlen
By Trading Economics
Einkommen	-136K -35M
EPS	-0.503
Angestellte	106
EBITDA	-619K -38M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+86.67% upside

Dividenden
By Acuity
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 261M
Vorheriger Eröffnungskurs	-3.39
Vorheriger Schlusskurs	3.75

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Juni 2026, 23:52 UTC

China's House Price Index YoY release on June 16, 2026, faces cautious market sentiment amid ongoing declines and geopolitical tensions.

13. Juni 2026, 23:51 UTC

Correlated Moves

Bitcoin has advanced since Friday, reflecting positive sentiment in the cryptocurrency market. The asset remains below its 20-day moving average and near its one-month range low.

13. Juni 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Optimism Over U.S.-Iran Peace Talks, While Traders Anticipate Fed's Interest Rate Decision Amid Inflation Concerns.

13. Juni 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism, Fed Expected to Hold Rates Amid Geopolitical Tensions and Key Economic Data Ahead.

13. Juni 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism and Global Mineral Economy Shift Ahead of Steady Fed Rate Decision.

13. Juni 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Peace Deal Hopes, While Investors Brace for Key Economic Data and Fed Rate Decision.

13. Juni 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on June 18, 2026, Anticipates Growth Amid Mixed Economic Sentiment and Inflation Concerns.

13. Juni 2026, 23:31 UTC

U.S. Industrial Production MoM data for May 2026 expected to rise by 0.2% amid cautious optimism following April's strong performance of 0.7%.

13. Juni 2026, 23:21 UTC

U.S. Retail Sales MoM Report on June 17 Expected to Show Modest 0.5% Increase Amid Geopolitical Tensions and Consumer Spending Optimism

13. Juni 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Economic Resilience

13. Juni 2026, 23:21 UTC

Canada's New Housing Price Index set for June 17 release, with a forecasted slight decline amid ongoing affordability challenges and government announcements.

13. Juni 2026, 23:11 UTC

Market Anticipates U.S. Building Permits Data Release Amid Cautious Optimism and Economic Concerns on June 16, 2026.

13. Juni 2026, 23:02 UTC

India's RBI to release monetary policy meeting minutes amid lower-than-expected CPI inflation and rising food costs, influencing future interest rate decisions.

13. Juni 2026, 23:02 UTC

Upcoming U.S. Housing Starts Data Release on June 16, 2026 Expected to Reflect Economic Conditions Amid Government Initiatives and Rising Demand.

13. Juni 2026, 23:02 UTC

Investors Anticipate Further Increases in U.S. Export Prices Ahead of June 16 Release Amid Geopolitical Developments

13. Juni 2026, 23:02 UTC

U.S. Housing Starts Expected to Reach 1.44 Million Units in May Amid Mixed Trends and Policy Discussions Ahead of June 16 Release

13. Juni 2026, 23:02 UTC

U.S. Import Prices Report on June 16 Expected to Show 0.9% Increase Amid Geopolitical Optimism and Inflation Concerns

13. Juni 2026, 23:02 UTC

Market Anticipates 1.41 Million Building Permits in May 2026 Amidst Cautious Optimism for Housing Sector Recovery.

13. Juni 2026, 23:01 UTC

Macro News

DAX 30 Index rises in after-market trading amid optimism for a U.S.-Iran peace deal and President Trump's announcement on the Strait of Hormuz.

13. Juni 2026, 22:51 UTC

Japan's Year-on-Year Inflation Rate Release on June 18 Expected to Show Stability Amid Mixed Economic Signals and Global Influences.

13. Juni 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Hold at 1.4% Amid Cautious Market Sentiment and BOJ Policy Considerations

13. Juni 2026, 22:41 UTC

Market anticipates June 15 release of NY Empire State Manufacturing Index at 13.2, signaling cautious optimism amid inflation concerns and geopolitical developments.

13. Juni 2026, 22:41 UTC

Japan's Machinery Orders Expected to Rise 0.9% in April Amidst Mixed Economic Signals and Improving Investor Confidence

13. Juni 2026, 22:41 UTC

Japan's Exports Expected to Rise 0.162% YoY in June Amid Positive Economic Sentiment and Geopolitical Easing, Despite Competition from China

13. Juni 2026, 22:41 UTC

Mortgage Rates Set to Rise Amid Geopolitical Tensions and Economic Uncertainty, with Upcoming MBA Report Expected on June 17.

13. Juni 2026, 22:32 UTC

UK Consumer Confidence Index for June 2026 Forecasted at -23 Amid Ongoing Inflation and Economic Uncertainty

13. Juni 2026, 22:32 UTC

Canada's May 2026 Housing Starts Data Set for Release, Forecasted at 255K Units Amid Optimistic Market Sentiment and Government Initiatives.

13. Juni 2026, 22:32 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on June 15, Amidst Cautious Market Sentiment and Global Economic Influences.

13. Juni 2026, 22:32 UTC

Japan's trade deficit forecasted at -564.6 billion yen amid high import costs, but market optimism rises following easing U.S.-Iran tensions and strong Asian stock performance.

13. Juni 2026, 22:32 UTC

Brazil's Retail Sales Report on June 16 Expected to Show Resilience Amid Mixed Economic Signals

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

86.67% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD 86.67%

Hoch 10 USD

Tief 4 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zentalis Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.